Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies
Summary Background Enterocyte damage is the hallmark of coeliac disease (CD) resulting in malabsorption. Little is known about the recovery of enterocyte damage and its clinical consequences. Serum intestinal fatty acid binding protein (I‐FABP) is a sensitive marker to study enterocyte damage. Aims...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2013-02, Vol.37 (4), p.482-490 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 490 |
|---|---|
| container_issue | 4 |
| container_start_page | 482 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 37 |
| creator | Adriaanse, M. P. M. Tack, G. J. Passos, V. Lima Damoiseaux, J. G. M. C. Schreurs, M. W. J. Wijck, K. Riedl, R. G. Masclee, A. A. M. Buurman, W. A. Mulder, C. J. J. Vreugdenhil, A. C. E. |
| description | Summary
Background
Enterocyte damage is the hallmark of coeliac disease (CD) resulting in malabsorption. Little is known about the recovery of enterocyte damage and its clinical consequences. Serum intestinal fatty acid binding protein (I‐FABP) is a sensitive marker to study enterocyte damage.
Aims
To evaluate the severity of enterocyte damage in adult‐onset CD and its course upon a gluten‐free diet (GFD). Furthermore, the correlation among enterocyte damage, CD autoantibodies and histological abnormalities during the course of disease is studied.
Methods
Serum I‐FABP levels were determined in 96 biopsy‐proven adult CD patients and in 69 patients repeatedly upon a GFD. A total of 141 individuals with normal antitissue transglutaminase antibody (IgA‐tTG) levels served as controls. I‐FABP levels were related to the degree of villous atrophy (Marsh grade) and IgA‐tTG.
Results
I‐FABP levels were elevated in untreated CD (median 691 pg/mL) compared with controls (median 178 pg/mL, P |
| doi_str_mv | 10.1111/apt.12194 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_apt_12194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>APT12194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3904-e3be9ba8936167069387585d7f62e75b75dfeaa88d665f0831166638afbb93253</originalsourceid><addsrcrecordid>eNp10L9OHDEQBnArCgoXSJEXQG5SUOzhP9hrlxfEBSQkkDjq1ax3ljjsrU-2F3QdBQ-QZ8yTsMcBqZhmmp_m03yEfOdsysc5glWecsHt8Scy4VKrQjCpP5MJE9oWwnC5S76m9IcxpksmvpBdIYWxStoJebrGOCzp-b_Hv_PZzysKiS4h3mGkbYgU-4wxuHVG2sASbpH6nrqAnQdHG58QElLoG-pzohE7yD70NAd677suDIlCjmH1e_1inI9u2JD-lsKQA_TZ16HxmPbJTgtdwm-ve4_czE8XJ2fFxeWv85PZReGkZccFyhptDcZKzcdHtJWmVEY1ZasFlqouVdMigDGN1qplRnKutZYG2rq2Uii5Rw63d10MKUVsq1X047vrirNq02Q1Nlm9NDnag61dDfUSm3f5Vt0IfrwCSA66NkLvfPrvtJFGST26o6178B2uP06sZleLbfQzRoiMew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Adriaanse, M. P. M. ; Tack, G. J. ; Passos, V. Lima ; Damoiseaux, J. G. M. C. ; Schreurs, M. W. J. ; Wijck, K. ; Riedl, R. G. ; Masclee, A. A. M. ; Buurman, W. A. ; Mulder, C. J. J. ; Vreugdenhil, A. C. E.</creator><creatorcontrib>Adriaanse, M. P. M. ; Tack, G. J. ; Passos, V. Lima ; Damoiseaux, J. G. M. C. ; Schreurs, M. W. J. ; Wijck, K. ; Riedl, R. G. ; Masclee, A. A. M. ; Buurman, W. A. ; Mulder, C. J. J. ; Vreugdenhil, A. C. E.</creatorcontrib><description>Summary
Background
Enterocyte damage is the hallmark of coeliac disease (CD) resulting in malabsorption. Little is known about the recovery of enterocyte damage and its clinical consequences. Serum intestinal fatty acid binding protein (I‐FABP) is a sensitive marker to study enterocyte damage.
Aims
To evaluate the severity of enterocyte damage in adult‐onset CD and its course upon a gluten‐free diet (GFD). Furthermore, the correlation among enterocyte damage, CD autoantibodies and histological abnormalities during the course of disease is studied.
Methods
Serum I‐FABP levels were determined in 96 biopsy‐proven adult CD patients and in 69 patients repeatedly upon a GFD. A total of 141 individuals with normal antitissue transglutaminase antibody (IgA‐tTG) levels served as controls. I‐FABP levels were related to the degree of villous atrophy (Marsh grade) and IgA‐tTG.
Results
I‐FABP levels were elevated in untreated CD (median 691 pg/mL) compared with controls (median 178 pg/mL, P < 0.001) and correlated with Marsh grade (r = 0.265, P < 0.05) and IgA‐tTG (r = 0.403, P < 0.01). Upon a GFD serum levels decreased significantly, however, not within the range observed in controls, despite the common observed normalisation of IgA‐tTG levels and Marsh grade. CD patients with elevated I‐FABP levels nonresponding to GFD showed persistent histological abnormalities.
Conclusions
Enterocyte damage assessed by serum I‐FABP correlates with the severity of villous atrophy in coeliac disease at the time of diagnosis. Although enterocyte damage improves upon treatment, substantial enterocyte damage persists despite absence of villous atrophy and low IgA‐tTG levels in the majority of cases. Elevated I‐FABP levels nonresponding to gluten‐free diet are indicative of histological abnormalities and warrant further evaluation.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.12194</identifier><identifier>PMID: 23289539</identifier><language>eng</language><publisher>Oxford: Blackwell</publisher><subject>Adult ; Aged ; Atrophy ; Autoantibodies - blood ; Biological and medical sciences ; Biomarkers - blood ; Celiac Disease - blood ; Celiac Disease - diet therapy ; Diet, Gluten-Free ; Digestive system ; Duodenum - pathology ; Enterocytes - pathology ; Fatty Acid-Binding Proteins - blood ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; GTP-Binding Proteins - immunology ; Humans ; Immunoglobulin A - blood ; Male ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Transglutaminases - immunology</subject><ispartof>Alimentary pharmacology & therapeutics, 2013-02, Vol.37 (4), p.482-490</ispartof><rights>2013 Blackwell Publishing Ltd</rights><rights>2014 INIST-CNRS</rights><rights>2013 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3904-e3be9ba8936167069387585d7f62e75b75dfeaa88d665f0831166638afbb93253</citedby><cites>FETCH-LOGICAL-c3904-e3be9ba8936167069387585d7f62e75b75dfeaa88d665f0831166638afbb93253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.12194$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.12194$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26838536$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23289539$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adriaanse, M. P. M.</creatorcontrib><creatorcontrib>Tack, G. J.</creatorcontrib><creatorcontrib>Passos, V. Lima</creatorcontrib><creatorcontrib>Damoiseaux, J. G. M. C.</creatorcontrib><creatorcontrib>Schreurs, M. W. J.</creatorcontrib><creatorcontrib>Wijck, K.</creatorcontrib><creatorcontrib>Riedl, R. G.</creatorcontrib><creatorcontrib>Masclee, A. A. M.</creatorcontrib><creatorcontrib>Buurman, W. A.</creatorcontrib><creatorcontrib>Mulder, C. J. J.</creatorcontrib><creatorcontrib>Vreugdenhil, A. C. E.</creatorcontrib><title>Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Enterocyte damage is the hallmark of coeliac disease (CD) resulting in malabsorption. Little is known about the recovery of enterocyte damage and its clinical consequences. Serum intestinal fatty acid binding protein (I‐FABP) is a sensitive marker to study enterocyte damage.
Aims
To evaluate the severity of enterocyte damage in adult‐onset CD and its course upon a gluten‐free diet (GFD). Furthermore, the correlation among enterocyte damage, CD autoantibodies and histological abnormalities during the course of disease is studied.
Methods
Serum I‐FABP levels were determined in 96 biopsy‐proven adult CD patients and in 69 patients repeatedly upon a GFD. A total of 141 individuals with normal antitissue transglutaminase antibody (IgA‐tTG) levels served as controls. I‐FABP levels were related to the degree of villous atrophy (Marsh grade) and IgA‐tTG.
Results
I‐FABP levels were elevated in untreated CD (median 691 pg/mL) compared with controls (median 178 pg/mL, P < 0.001) and correlated with Marsh grade (r = 0.265, P < 0.05) and IgA‐tTG (r = 0.403, P < 0.01). Upon a GFD serum levels decreased significantly, however, not within the range observed in controls, despite the common observed normalisation of IgA‐tTG levels and Marsh grade. CD patients with elevated I‐FABP levels nonresponding to GFD showed persistent histological abnormalities.
Conclusions
Enterocyte damage assessed by serum I‐FABP correlates with the severity of villous atrophy in coeliac disease at the time of diagnosis. Although enterocyte damage improves upon treatment, substantial enterocyte damage persists despite absence of villous atrophy and low IgA‐tTG levels in the majority of cases. Elevated I‐FABP levels nonresponding to gluten‐free diet are indicative of histological abnormalities and warrant further evaluation.</description><subject>Adult</subject><subject>Aged</subject><subject>Atrophy</subject><subject>Autoantibodies - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Celiac Disease - blood</subject><subject>Celiac Disease - diet therapy</subject><subject>Diet, Gluten-Free</subject><subject>Digestive system</subject><subject>Duodenum - pathology</subject><subject>Enterocytes - pathology</subject><subject>Fatty Acid-Binding Proteins - blood</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>GTP-Binding Proteins - immunology</subject><subject>Humans</subject><subject>Immunoglobulin A - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other diseases. Semiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Transglutaminases - immunology</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10L9OHDEQBnArCgoXSJEXQG5SUOzhP9hrlxfEBSQkkDjq1ax3ljjsrU-2F3QdBQ-QZ8yTsMcBqZhmmp_m03yEfOdsysc5glWecsHt8Scy4VKrQjCpP5MJE9oWwnC5S76m9IcxpksmvpBdIYWxStoJebrGOCzp-b_Hv_PZzysKiS4h3mGkbYgU-4wxuHVG2sASbpH6nrqAnQdHG58QElLoG-pzohE7yD70NAd677suDIlCjmH1e_1inI9u2JD-lsKQA_TZ16HxmPbJTgtdwm-ve4_czE8XJ2fFxeWv85PZReGkZccFyhptDcZKzcdHtJWmVEY1ZasFlqouVdMigDGN1qplRnKutZYG2rq2Uii5Rw63d10MKUVsq1X047vrirNq02Q1Nlm9NDnag61dDfUSm3f5Vt0IfrwCSA66NkLvfPrvtJFGST26o6178B2uP06sZleLbfQzRoiMew</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Adriaanse, M. P. M.</creator><creator>Tack, G. J.</creator><creator>Passos, V. Lima</creator><creator>Damoiseaux, J. G. M. C.</creator><creator>Schreurs, M. W. J.</creator><creator>Wijck, K.</creator><creator>Riedl, R. G.</creator><creator>Masclee, A. A. M.</creator><creator>Buurman, W. A.</creator><creator>Mulder, C. J. J.</creator><creator>Vreugdenhil, A. C. E.</creator><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201302</creationdate><title>Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies</title><author>Adriaanse, M. P. M. ; Tack, G. J. ; Passos, V. Lima ; Damoiseaux, J. G. M. C. ; Schreurs, M. W. J. ; Wijck, K. ; Riedl, R. G. ; Masclee, A. A. M. ; Buurman, W. A. ; Mulder, C. J. J. ; Vreugdenhil, A. C. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3904-e3be9ba8936167069387585d7f62e75b75dfeaa88d665f0831166638afbb93253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Atrophy</topic><topic>Autoantibodies - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Celiac Disease - blood</topic><topic>Celiac Disease - diet therapy</topic><topic>Diet, Gluten-Free</topic><topic>Digestive system</topic><topic>Duodenum - pathology</topic><topic>Enterocytes - pathology</topic><topic>Fatty Acid-Binding Proteins - blood</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>GTP-Binding Proteins - immunology</topic><topic>Humans</topic><topic>Immunoglobulin A - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other diseases. Semiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Transglutaminases - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adriaanse, M. P. M.</creatorcontrib><creatorcontrib>Tack, G. J.</creatorcontrib><creatorcontrib>Passos, V. Lima</creatorcontrib><creatorcontrib>Damoiseaux, J. G. M. C.</creatorcontrib><creatorcontrib>Schreurs, M. W. J.</creatorcontrib><creatorcontrib>Wijck, K.</creatorcontrib><creatorcontrib>Riedl, R. G.</creatorcontrib><creatorcontrib>Masclee, A. A. M.</creatorcontrib><creatorcontrib>Buurman, W. A.</creatorcontrib><creatorcontrib>Mulder, C. J. J.</creatorcontrib><creatorcontrib>Vreugdenhil, A. C. E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adriaanse, M. P. M.</au><au>Tack, G. J.</au><au>Passos, V. Lima</au><au>Damoiseaux, J. G. M. C.</au><au>Schreurs, M. W. J.</au><au>Wijck, K.</au><au>Riedl, R. G.</au><au>Masclee, A. A. M.</au><au>Buurman, W. A.</au><au>Mulder, C. J. J.</au><au>Vreugdenhil, A. C. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2013-02</date><risdate>2013</risdate><volume>37</volume><issue>4</issue><spage>482</spage><epage>490</epage><pages>482-490</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Enterocyte damage is the hallmark of coeliac disease (CD) resulting in malabsorption. Little is known about the recovery of enterocyte damage and its clinical consequences. Serum intestinal fatty acid binding protein (I‐FABP) is a sensitive marker to study enterocyte damage.
Aims
To evaluate the severity of enterocyte damage in adult‐onset CD and its course upon a gluten‐free diet (GFD). Furthermore, the correlation among enterocyte damage, CD autoantibodies and histological abnormalities during the course of disease is studied.
Methods
Serum I‐FABP levels were determined in 96 biopsy‐proven adult CD patients and in 69 patients repeatedly upon a GFD. A total of 141 individuals with normal antitissue transglutaminase antibody (IgA‐tTG) levels served as controls. I‐FABP levels were related to the degree of villous atrophy (Marsh grade) and IgA‐tTG.
Results
I‐FABP levels were elevated in untreated CD (median 691 pg/mL) compared with controls (median 178 pg/mL, P < 0.001) and correlated with Marsh grade (r = 0.265, P < 0.05) and IgA‐tTG (r = 0.403, P < 0.01). Upon a GFD serum levels decreased significantly, however, not within the range observed in controls, despite the common observed normalisation of IgA‐tTG levels and Marsh grade. CD patients with elevated I‐FABP levels nonresponding to GFD showed persistent histological abnormalities.
Conclusions
Enterocyte damage assessed by serum I‐FABP correlates with the severity of villous atrophy in coeliac disease at the time of diagnosis. Although enterocyte damage improves upon treatment, substantial enterocyte damage persists despite absence of villous atrophy and low IgA‐tTG levels in the majority of cases. Elevated I‐FABP levels nonresponding to gluten‐free diet are indicative of histological abnormalities and warrant further evaluation.</abstract><cop>Oxford</cop><pub>Blackwell</pub><pmid>23289539</pmid><doi>10.1111/apt.12194</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2013-02, Vol.37 (4), p.482-490 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_crossref_primary_10_1111_apt_12194 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Atrophy Autoantibodies - blood Biological and medical sciences Biomarkers - blood Celiac Disease - blood Celiac Disease - diet therapy Diet, Gluten-Free Digestive system Duodenum - pathology Enterocytes - pathology Fatty Acid-Binding Proteins - blood Female Gastroenterology. Liver. Pancreas. Abdomen GTP-Binding Proteins - immunology Humans Immunoglobulin A - blood Male Medical sciences Middle Aged Other diseases. Semiology Pharmacology. Drug treatments Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Transglutaminases - immunology |
| title | Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A15%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20I%E2%80%90FABP%20as%20marker%20for%20enterocyte%20damage%20in%20coeliac%20disease%20and%20its%20relation%20to%20villous%20atrophy%20and%20circulating%20autoantibodies&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Adriaanse,%20M.%20P.%20M.&rft.date=2013-02&rft.volume=37&rft.issue=4&rft.spage=482&rft.epage=490&rft.pages=482-490&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.12194&rft_dat=%3Cwiley_cross%3EAPT12194%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23289539&rfr_iscdi=true |